Trials In Focus

August 25, 2010

Inside Stories – Wide brief for cancer candidate

A group of three Phase I trials being run by local CRO Novotech is casting a wide net for OncoMed’s cancer-fighting humanised monoclonal antibody OMP-21M18. The aim of all three trials is to determine the safety, efficacy, pharmacokinetics and maximum tolerated dose of OMR-21M18 when combined with standard of care chemotherapy regimes in several different cancers.

By Simone du Toit

Other relevant content